Johnson & Johnson has dropped three percent in premarket trading in what appears to be a response to its halting of trials for a coronavirus vaccine, Business Insider reports.
Yesterday the company (which owns Janssen Pharmaceuticals) announced that it had paused phase 3 of its vaccine trials, after a trial volunteer became ill. The volunteer was one of 60,000 trial participants.